It marks cancer cells by inducing the expression of NY-ESO-1 in tumors that are limited in therapeutic targets (referred to as “Mark”), and it can be combined with NY-ESO-1-specific TCR-T cell therapy to maximize tumor cell killing (referred to as “Kill”). Here, CTAG1B is linked to neoplasm.